Clare Balendran graduated from University of Nottingham and completed a PhD from University of Wales College of Medicine, UK. She developed her interest in molecular signalling as a Post-doctoral Fellow in the lab of Sir Philip Cohen, University of Dundee and Cyclacel, UK.
Clare moved to AstraZeneca, Sweden in 2002 where she held roles of increasing seniority in Line and Project Leadership. In 2011, Clare switched fields to Personalised Healthcare as one of the early pioneers to implement Precision Medicine and Diagnostics in Cardiovascular and Metabolic Diseases.
Clare joined Novo Nordisk, Denmark in 2019 to continue her passion for increasing the biological understanding of complex diseases. She holds the position of Vice President and Head of Translational Development, where Clare, together with her team, is responsible for the organisational and strategic build of Translational Medicine, Precision Medicine and Diagnostics as a new discipline at Novo Nordisk.
